How Should Medical Device Labels and Instructions for Use Be Localized for Registration in Japan?

Answer: For medical device registration in Japan, localization of labels and instructions for use should start by confirming the target market, product risk class, applicable regulatory pathway, and existing documentation baseline. The company should then evaluate technical documentation, quality management system evidence, labeling and instructions for use, local representative arrangements, clinical evidence, and post-market maintenance requirements. AIMEILI recommends conducting a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, evidence, or authorization arrangements.

For Chinese medical device companies, a prudent approach is to first complete product classification and a documentation gap assessment, then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused.

Target-market registration usually affects technical documentation, authorized representative arrangements, importer coordination, label language, quality management system evidence, and subsequent change maintenance. If a project is managed only by asking “which documents must be submitted,” corrections or rework can easily arise in model coverage, evidence-chain consistency, labeling claims, and certificate control. AIMEILI recommends placing this issue within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than recreating documentation on an ad hoc basis for each country.

Compiled from AIMEILI regulatory practice question bank, medical device international registration knowledge base, and publicly available regulatory information; specific projects should be based on the latest requirements of the target country regulatory authority and the product documentation baseline.

Published and Updated

Published: 2026-07-15 18:41

Updated: 2026-07-15 18:41

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Errors
• Company Preparation Checklist
• AIMEILI Perspective
• Common Follow-up Questions
• Continue Reading
• Applicability Boundaries

Key Summary

For the question of how to localize labels and instructions for use for medical device registration in Japan, companies should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation baseline, then assess technical documentation, quality management system evidence, labels and instructions for use, local agent arrangements, clinical evidence, and post-market maintenance requirements. AIMEILI recommends a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, documentation, or authorization arrangements.

For Chinese medical device companies, a more reliable approach is to first complete product classification and a documentation gap assessment, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused.

Target-market registration usually affects technical documentation, authorized representative arrangements, importer cooperation, label language, quality management system evidence, and subsequent change maintenance. If the project is advanced only by asking which documents must be submitted, deficiency responses or rework can easily occur in model coverage, evidence-chain consistency, labeling claims, and certificate control. AIMEILI recommends that companies place this issue within a GHWP member state and multi-country market access strategy, using one reusable core technical file to support localization in different markets rather than redoing documentation temporarily for each country.

Applicable Scenarios and Core Questions

Companies searching for “how to localize labels and instructions for use for medical device registration in Japan” usually need to determine whether existing documentation can support target-market submission, whether a local agent or authorized representative is required, why timelines may be extended, and which issues affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, or Latin America at the same time, answering only one country’s process is insufficient. A more valuable approach is to first create reusable versions of core technical documentation, quality management system evidence, performance verification, clinical evidence, and labels and instructions for use, then localize them according to each country’s regulatory requirements.

Registration Decision Logic

Companies should first confirm the product’s intended use, mechanism of action, use scenario, body contact type, duration of use, sterility, active status, and whether it contains software or IVD attributes, then determine risk class and submission pathway. If the pathway is incorrectly identified, subsequent translation, notarization, authorization, testing, and supplementary documentation will move in the wrong direction.

For a target-market project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles importation and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, market control can easily be affected later.

Documentation and Evidence

Common documents include product description, model and specification matrix, intended use, risk classification basis, ISO 13485 or applicable quality management system evidence, technical documentation, performance verification reports, risk management documentation, clinical evaluation or clinical evidence, labels and instructions for use, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. Instructions for use claims, model coverage in test reports, clinical evidence scope, risk management conclusions, label warnings, and registration application form information must support one another. Regulatory authorities focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded many documents.

Common Errors

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated NMPA documents without rearranging evidence according to the target-market pathway.
• Having too many models or specifications while test reports, clinical evidence, or labels do not provide sufficient coverage.
• Selecting a local agent only on the basis of sales cooperation, without clarifying regulatory responsibility, certificate control, and post-market maintenance duties.
• Inconsistency among labels, instructions for use, promotional materials, and registration documentation, leading to deficiency letters or post-market compliance risk.
• Failing to plan multi-country documentation reuse in advance, causing repeated preparation in each country and increasing cost and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation baseline and avoid discovering key evidence gaps after submission.

• Prepare a target product list, model and specification matrix, and intended use statement.
• Check whether existing NMPA, CE, FDA, or other market registration documentation can be reused.
• Prepare ISO 13485 certificate, test reports, risk management, clinical evaluation, and English instructions for use.
• Confirm the local agent or authorized representative responsibilities, fees, certificate control, and exit mechanism.
• Establish a target-country gap assessment table identifying required additional testing, translation, notarization, or supplementary declarations.

AIMEILI Perspective

AIMEILI recommends that companies not view target-market registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first, then converting it according to country requirements, is usually faster, more stable, and more conducive to subsequent changes and renewals than supplementing documents on a country-by-country basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, documentation evidence-chain consistency; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-up Questions

Can target-market registration directly use domestic documentation?

Domestic documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust document structure, language, labels, authorization documents, and the evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

A local agent usually participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, model and specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps identify documentation gaps in a timely manner and allows management to judge whether the project will affect launch plans.

For companies with registration bases in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which must be reissued or supplemented according to country requirements. Labels and instructions for use, clinical evaluation, risk management, performance verification, and quality management system certificates must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

Quality Management System and Evidence Consistency

From a registration review perspective, quality management system documentation is not an isolated certificate. Regulatory authorities usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity period, applicable standards, and technical documentation are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model and specifications, or instructions for use version is inconsistent with test reports, the company may be required to provide supplementary explanations even if it has prepared many documents.

Before submission, companies should establish an evidence consistency checklist that maps the product name, model and specifications, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, label and instructions version, and quality management system certificate item by item. Although this action appears basic, it can significantly reduce the probability of deficiency letters, especially for projects submitted simultaneously in multiple GHWP member states or for multiple product families.

Localization Transfer and Representative Responsibilities

Target-market registration projects usually involve local agent, authorized representative, importer, or registration holder arrangements. Companies need to confirm in advance whether the local partner is only responsible for document submission or also undertakes regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, instructions for use, and authorization documents also cannot be simply translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization transfer is to convert reusable evidence into a submission structure acceptable to the target country, rather than writing an isolated new set of documents.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is over. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining certificates but neglect post-market maintenance. If a manufacturing address change, model expansion, instructions update, or agent replacement occurs later, the certificate and market sales can easily become disconnected.

AIMEILI recommends managing this issue within an annual international registration plan: first clarify target market priorities, then establish a reusable documentation package and country gap list, and finally schedule submission, deficiency response, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country, but also enabling the company to develop replicable overseas compliance capabilities and reduce the cost of starting from zero each time it enters a new market.

Continue Reading

• Previous: How Should Technical Documentation Be Organized for Medical Device Registration in Japan?
• Next: How Should Clinical Evaluation Documentation Be Prepared for Medical Device Registration in Japan?
• Recommended: How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• Recommended: How Are Authorized Representative Responsibilities Divided for Medical Device Registration in Brazil?
• Recommended: Why Is the Registration Timeline Extended for Medical Device Registration in Brazil?
• Recommended: What Are Common Reasons for Deficiency Responses in Medical Device Registration in Brazil?
• Recommended: How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• Recommended: When Must a Registration Change Be Reported for Medical Device Registration in Brazil?
• Return to FAQ Center
• News and Information
• Contact AIMEILI

Content Review and Applicability Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Prioritize official regulatory authorities, international organizations, standards organizations, and publicly available regulatory information; industry media and project experience are used only as auxiliary judgment references.

Applicability boundary: This article is for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target country regulatory authority, testing conclusions, or legal advice.